The cohort randomized to inhaled tobramycin and reporting azithromycin use showed a significant decrease in the percent predicted FEV@ after one and three courses of inhaled tobramycin when compared with those not reporting azithromycin use ( @ d : -@ vs. @ % , P < @ ; @ d : -@ vs. @ % , P < @ ) .